• Home
  • Pharmaceuticals and Healthcare
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Opportunities and Forecast 2022-2028

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Opportunities and Forecast 2022-2028

Report Code: KNJ1112008 | No. of Pages: 135 | Category: Pharmaceuticals and Healthcare
Publisher: GRD Survey | Date of Publish: Jan-2022 
This report provides a comprehensive analysis of current global Amyotrophic Lateral Sclerosis (ALS) Treatment market based on segmented types and downstream applications. Major product development trends are discussed  under major downstream segment scenario. This report also focuses on major driving factors and inhibitors that affect the market and competitive landscape. Global and regional leading players in the Amyotrophic Lateral Sclerosis (ALS) Treatment industry are profiled in a detailed way, with sales data and market share info. This report also includes global and regional market size and forecast, drill-down to top 20 economies.

According to this survey, the global Amyotrophic Lateral Sclerosis (ALS) Treatment market is estimated at $ 300 million in 2021, and projected to grow at a CAGR of 9.1% to $ 540 million by 2028.

Covid-19 pandemic has impacted the supply and demand status for many industries along the supply chain. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Opportunties and Forecast 2022-2028 report makes a brilliant attempt to unveil key opportunities available in the global Amyotrophic Lateral Sclerosis (ALS) Treatment market under the covid-19 impact to help readers in achieving a better market position. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information.

The Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market has been exhibited in detail in the following chapters
Chapter 1 displays the basic product introduction and market overview.
Chapter 2 provides the competition landscape of global Amyotrophic Lateral Sclerosis (ALS) Treatment industry. 
Chapter 3 provides the market analysis by type and by region
Chapter 4 provides the market analysis by application and by region
Chapter 5-10 presents regional and country market size and forecast, under the context of market drivers and inhibitors analysis. 
Chapter 11 analyses the supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis.
Chapter 12 provides the market forecast by type and by application
Chapter 13 provides the market forecast by region
Chapter 14 profiles global leading players with their revenue, market share, profit margin, major product portfolio and SWOT analysis.
Chapter 15 conclusions


Segmented by Type
    Riluzole

    Edaravone (Radicava)


Segmented by Application
    Hospital

    Drugs Store

    Other

Segmented by Country
    North America
        United States
        Canada
        Mexico
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Spain
    Asia Pacific
        China
        Japan
        Korea
        Southeast Asia
        India
        Australasia
    Central & South America
        Brazil
        Argentina
        Colombia
    Middle East & Africa
        Iran
        Israel
        Turkey
        South Africa
        Saudi Arabia

Key manufacturers included in this survey
    Mylan Pharma

    Mitsubishi Tanabe Pharma

    Lunan Pharma

    Glemark Generics

    Covis Pharma

    Apotex



Table of Contents

1 Product Introduction and Overview
    1.1 Product Definition
    1.2 Product Specification
    1.3 Global Market Overview
        1.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Status and Forecast (2016-2027)
        1.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value CAGR by Region
    1.4 Market Drivers, Inhibitors
        1.4.1 Market Drivers
        1.4.2 Market Inhibitors
        1.4.3 COVID-19 Impact Analysis
2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Supply by Company
    2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Volume by Company
    2.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Company
    2.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Price by Company
    2.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Production Location and Sales Area of Main Manufacturers
    2.5 Trend of Concentration Rate
3 Global and Regional Amyotrophic Lateral Sclerosis (ALS) Treatment Market Status by Type
    3.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Type Introduction
        3.1.1 Riluzole

        3.1.2 Edaravone (Radicava)

        3.1.3 Other
    3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Type
        3.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Volume by Type (2016-2021)
        3.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Type (2016-2021)
        3.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Price by Type (2016-2021)
    3.3 North America: by Type
    3.4 Europe: by Type
    3.5 Asia Pacific: by Type
    3.6 Central & South America: by Type
    3.7 Middle East & Africa: by Type
4 Global and Regional Amyotrophic Lateral Sclerosis (ALS) Treatment Market Status by Application
    4.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Application
        4.1.1 Hospital

        4.1.2 Drugs Store

        4.1.3 Other
    4.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Application
        4.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Volume by Application (2016-2021)
        4.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Application (2016-2021)
        4.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Price by Application (2016-2021)
    4.3 North America: by Application
    4.4 Europe: by Application
    4.5 Asia Pacific: by Application
    4.6 Central & South America: by Application
    4.7 Middle East & Africa: by Application
5 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Status by Region
    5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Region
        5.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Volume by Region
        5.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Region
    5.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Status
    5.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Status
    5.4 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Status
    5.5 Central & South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Status
    5.6 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Status
6 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Status
    6.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country
        6.1.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Volume by Country (2016-2021)
        6.1.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Country (2016-2021)
    6.2 United States
    6.3 Canada
    6.4 Mexico
7 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Status
    7.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country
        7.1.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Volume by Country (2016-2021)
        7.1.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Country (2016-2021)
    7.2 Germany
    7.3 France
    7.4 UK
    7.5 Italy
    7.6 Russia
    7.7 Spain
8 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Status
   8.1 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country
        8.1.1 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Volume by Country (2016-2021)
        8.1.2 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Country (2016-2021)
    8.2 China
    8.3 Japan
    8.4 Korea
    8.5 Southeast Asia
    8.6 India
    8.7 Australasia
9 Central & South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Status
    9.1 Central & South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country
        9.1.1 Central & South America Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Volume by Country (2016-2021)
        9.1.2 Central & South America Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Country (2016-2021)
    9.2 Brazil
    9.3 Argentina
    9.4 Colombia
10 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Status
    10.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country
        10.1.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Volume by Country (2016-2021)
        10.1.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value by Country (2016-2021)
    10.2 Iran
    10.3 Israel
    10.4 Turkey
    10.5 South Africa
    10.8 Saudi Arabia
11 Supply Chain and Manufacturing Cost Analysis
    11.1 Supply Chain Analysis
    11.2 Production Process Chart Analysis
    11.3 Raw Materials and Key Suppliers Analysis
        11.3.1 Raw Materials Introduction
        11.3.2 Raw Materials Key Suppliers List
    11.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Manufacturing Cost Analysis
    11.5 Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Channel and Distributors Analysis
        11.5.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Channel
        11.5.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Distributors
    11.6 Amyotrophic Lateral Sclerosis (ALS) Treatment Downstream Major Buyers
12 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast by Type and by Application
    12.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Volume and Sales Value Forecast (2022-2027)
    12.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast by Type
        12.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Volume Forecast by Type
        12.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Forecast by Type
        12.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Price Forecast by Type
    12.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast by Application
        12.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Volume Forecast by Application
        12.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Forecast by Application
        12.3.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Price Forecast by Application
13 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast by Region/Country
    13.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast by Region (2022-2027)
        13.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Volume Forecast by Region (2022-2027)
        13.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Value Forecast by Region (2022-2027)
    13.2 North America Market Forecast
    13.3 Europe Market Forecast
    13.4 Asia Pacific Market Forecast
    13.5 Central & South America Market Forecast
    13.6 Middle East & Africa Market Forecast
14 Key Participants Company Information
    14.1 Sun Pharma

        14.1.1 Company Information
        14.1.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Introduction
        14.1.3 Sun Pharma
 Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
        14.1.4 SWOT Analysis
    14.2 Sanofi

        14.2.1 Company Information
        14.2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Introduction
        14.2.3 Sanofi
 Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
        14.2.4 SWOT Analysis
    14.3 Mylan Pharma

        14.3.1 Company Information
        14.3.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Introduction
        14.3.3 Mylan Pharma
 Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
        14.3.4 SWOT Analysis
    14.4 Mitsubishi Tanabe Pharma

        14.4.1 Company Information
        14.4.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Introduction
        14.4.3 Mitsubishi Tanabe Pharma
 Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
        14.4.4 SWOT Analysis
    14.5 Lunan Pharma

        14.5.1 Company Information
        14.5.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Introduction
        14.5.3 Lunan Pharma
 Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
        14.5.4 SWOT Analysis
    14.6 Glemark Generics

        14.6.1 Company Information
        14.6.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Introduction
        14.6.3 Glemark Generics
 Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
        14.6.4 SWOT Analysis
    14.7 Covis Pharma

        14.7.1 Company Information
        14.7.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Introduction
        14.7.3 Covis Pharma
 Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
        14.7.4 SWOT Analysis
    14.8 Apotex

        14.8.1 Company Information
        14.8.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Introduction
        14.8.3 Apotex
 Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
        14.8.4 SWOT Analysis
15 Conclusion
16 Methodology

NEED Help?

If you need any help or guidance, please feel free to call us.

USA : +1 (661) 636 6162

INDIA : +91 9325802062

or

Write us on : sales@kandjmarketresearch.com